The specificity of the antibody response against Zika virus (ZIKV) is not well-characterized. This 22 is due, in part, to the antigenic similarity between ZIKV and closely related dengue virus (DENV) 23 serotypes. Since these and other similar viruses co-circulate, are spread by the same mosquito 24 species, and can cause similar acute clinical syndromes, it is difficult to disentangle ZIKV-25 specific antibody responses from responses to closely-related arboviruses in humans. Here we 26 use high-density peptide microarrays to profile anti-ZIKV antibody reactivity in pregnant and 27 non-pregnant macaque monkeys with known exposure histories and compare these results to 28 reactivity following DENV infection. We also compare cross-reactive binding of ZIKV-immune 29 sera to the full proteomes of 28 arboviruses. We independently confirm a purported ZIKV-30 specific IgG antibody response targeting ZIKV nonstructural protein 2B (NS2B) that was 31 recently reported in ZIKV-infected people and we show that antibody reactivity in pregnant 32 animals can be detected as late as 127 days post-infection (dpi). However, we also show that 33 these responses wane over time, sometimes rapidly, and in one case the response was elicited 34 following DENV infection in a previously ZIKV-exposed animal. These results suggest 35 epidemiologic studies assessing seroprevalence of ZIKV immunity using linear epitope-based 36 strategies will remain challenging to interpret due to susceptibility to false positive results.
outcomes for pregnant animals are described in Table 2 . Additional details on the study 116 histories of the animals in this study can be found at https://go.wisc.edu/b726s1. 0.05% Tween-20) for 1 h at room temperature, then the array was washed 2x for 1 min in 1x TBS, and washed once for 30 sec in reagent-grade water. Fluorescent signal of the secondary 202 antibody was detected by scanning at 635 nm at 2 µm resolution and 25% gain, using an 203 MS200 microarray scanner (Roche NimbleGen).
204

Peptide array data processing 205
The datafiles and analysis code for figures are available from https://go.wisc.edu/b726s1. All
206
figures use the log base 2 of the raw fluorescence signal intensity values. For each sample, 207 each unique peptide was assayed and processed once; then results from peptides redundant to 208 multiple proteomes (i.e. were present in more than one strain represented) were restored to 209 each protein.
211
For cumulative distribution function (CDF) plots, fluorescence signal intensities were log base 2 212 transformed and background reactivity in the blank (binding buffer only) control sample was 213 subtracted for each peptide. The fold change from 0 dpi was calculated by subtracting reactivity 214 at 0 dpi from reactivity at 28 dpi. To reduce instrument-related variance, the data was then 215 filtered by taking the minimum intensity of two consecutive peptides with 1 amino acid offset, 216 thereby reducing peptide outliers by ensuring measured reactivity occurs in multiple consecutive 217 peptides.
218
Validation of peptide array findings 219
To confirm the validity of our findings from this recently-developed peptide microarray platform, 220 we assessed its performance against the humoral response produced by infection with simian 221 immunodeficiency virus (SIV), which has been well-characterized by conventional methods such 222 as enzyme-linked immunosorbent assays (ELISAs), enzyme-linked immunosorbent spot assays peptides, overlapping by 12 amino acids, representing the SIVmac239 envelope protein (env) 225 and analyzed serum from two Mauritian cynomolgus macaques for SIV-specific IgG reactivity 226 before and approximately 125 days after SIVmac239 infection (Table 1 ). (We have previously 227 plotted data procured from peptide array assays of these samples [37] while investigating the 228 antibody response to SIV in the context of simian pegivirus infection; here we show the same 229 data using the updated, improved data processing pipeline described above). Post-infection 230 samples showed fluorescence intensity as high as 1,000 times the intensity in pre-infection 231 samples (Supplemental figure S1 ). Regions of higher-fold increases in fluorescence intensity 232 corresponded to previously defined variable domains of env which are known antibody targets, 233 the variable loop regions, as well as others corresponding to known epitopes [41, 42] . Taken 234 together, these results validate epitope definition on the peptide microarray platform and show 235 this platform to be capable of high-resolution virus-specific IgG epitope identification using the 236 analytic methods utilized here.
237
Results
238
Identification of linear B cell epitopes in the ZIKV polyprotein 239
We sought to determine antibody binding, or reactivity, to the ZIKV polyprotein following ZIKV 240 infection. We tiled 16-residue (16-mer) peptides overlapping by 15 amino acids representing 241 different ZIKV polyproteins and evaluated the antibody binding of serum samples from animals 242 with recent ZIKV-FP (animals B1, D1, and D2) or ZIKV-MR766 (animal C1) infections (Table 1) .
243
Animals in both groups had demonstrated neutralizing antibody responses at 28 dpi, measured 244 by 90% plaque reduction neutralization tests (PRNT90) as described previously [16, 38, 23] .
245
Peptides were defined as reactive if the signal intensity was greater after infection with a 246 cognate strain (e.g., increased signal intensity against ZIKV peptides in an animal infected with ZIKV) than it was before infection. Peptides were defined as cross-reactive if the signal intensity 248 was greater after infection with a noncognate strain (e.g., increased signal intensity against 249 ZIKV peptides in an animal infected with DENV). Statistical significance of the change in signal 250 intensity versus no change was calculated using a two-tailed log-ratio t-test. True epitopes were 251 expected to induce antibody binding to multiple peptides with overlapping sequences; thus 252 regions were only considered epitopes when there was a statistically significant increase in 253 intensity in a post-infection sample relative to intensity in a pre-infection sample in three or more 254 consecutive peptides.
256
Reactivity was most commonly observed in three regions of the flavivirus polyprotein: envelope 257 protein, NS2B, and nonstructural protein 3 (NS3); therefore, most of the analysis in this paper is 258 limited to these regions. Antibody binding to peptides from the envelope protein was seen in all 259 four animals at 28 dpi; antibody binding in the NS3 region was seen in three out of four animals 
270
All four animals exhibited antibody binding to the ZIKV NS2B epitope similar to that documented 271 in humans [12] . Though other reactive epitopes were identified in other proteins in multiple animals, this epitope was the only epitope in our study for which all ZIKV-infected animals 273 showed reactivity. All ten ZIKV-infected animals in this study were used to determine statistical 274 significance of this epitope in order to avoid making statistical inferences using very small 275 sample sizes [43] . Area under the curve (AUC) values and corresponding receiver operating 
306
Given this array's capacity to screen for antibody binding to peptides representing many 307 different virus proteomes at once, we also assessed cross-reactivity against the 27 other 308 arboviruses (for a total of 28 arboviruses) represented. We plotted the fold change in reactivity 309 from 0 to 28 dpi for each peptide in each virus's proteome using cumulative distribution function Table 3 ). 
369
All pregnant animals showed a similar pattern of anti-ZIKV reactivity, with some differences in 370 time to peak reactivity and duration of detectable reactivity. In G1, elevated baseline intensity in 371 the ZIKV NS2B1427-1451RD25 region was present prior to inoculation with ZIKV-FP. Reactivity 372 peaked in the acute phase (7 dpi) and subsequently decreased but remained above pre-infection levels through 127 dpi, after G1 had given birth. In G2, reactivity was not appreciable 374 until the early convalescent phase (21 dpi) and peaked at 35 dpi, remaining elevated relative to 375 pre-infection levels through the latest time point analyzed (113 dpi). Animals H1 and H3 showed 376 elevated pre-infection intensity against NS2B1427-1451RD25. All three animals in cohort H showed 377 reactivity by 21 dpi. H1 and H2 continued to exhibit increased reactivity through the latest time 378 point measured (70 dpi), while H3 had peak reactivity at 21 dpi and decreased after. I1, an 379 animal nine months post-DENV-3 infection, showed a pattern of reactivity similar to that in other 380 animals, with anti-NS2B1427-1451RD25 IgG reactivity first appearing at 8 dpi and peaking at 29 dpi 381 at a level 3.6 times pre-infection reactivity (Figure 4 ). Reactivity remained close to peak 382 reactivity through 78 dpi.
384
All pregnant animals' cross-reactivity against DENV polyproteins mirrored that seen in non-385 pregnant animals (supplemental figure S6 ).
386
Differentiating DENV serology in ZIKV-immune animals 387
Previous assays have struggled to distinguish DENV serologic responses from ZIKV serologic 388 responses [5] [6] [7] [8] . We investigated whether the peptide microarray technology, and specifically 389 reactivity patterns using the ZIKV NS2B1427-1451RD25 epitope, could distinguish DENV from ZIKV 390 infections. Three animals (cohort F) had been challenged twice with ZIKV-FP 12 months prior 391 and 9.5 months prior [16]; we collected serum from these animals, infected them with DENV-2, F1, F2, and F3) , with history of challenge and rechallenge with ZIKV-FP 12 and 9.5 months prior, were infected with DENV-2 and serum samples taken before 398 DENV infection and at 28 dpi were assessed. Reactivity of these animals against peptides 399 representing the envelope, NS2B, and NS3 proteins of DENV-2 (A) and ZIKV-FP (B) is shown.
400
The ZIKV NS2B1427-1451RD25 epitope (in B) is highlighted in grey.
402
These animals showed reactivity against all four DENV polyproteins in regions representing the 403 DENV envelope protein, DENV NS3, and others ( Figure 5A ) and cross-reactivity against 404 corresponding regions of the ZIKV polyprotein ( Figure 5B ). One animal (F3) out of the three 405 showed significant reactivity to the NS2B1427-1451RD25 epitope, though this reactivity was slightly 406 outside the area of typical NS2B1427-1451RD25 reactivity (peptides 1421-1444 rather than 1427-407 1451). Another (F1) showed elevated pre-DENV infection intensity in NS2B1427-1451RD25 that did 408 not change following DENV infection, possibly as a result of the animal's prior ZIKV exposure.
409
Animal F2 showed no detectable NS2B1427-1451RD25 reactivity before or after exposure.
410
Discussion
411
We describe the antibody binding of the anti-ZIKV IgG response in non-pregnant and pregnant 412 rhesus macaques and compare this to the anti-DENV response. Using a recently developed 413 high-density peptide microarray we show that macaques infected with ZIKV produce IgG 414 antibodies which bind throughout the ZIKV polyprotein, including conserved antibody binding to 415 an epitope in ZIKV NS2B, NS2B1427-1451RD25, which is apparent regardless of the ZIKV strain 416 used for infection. We establish that cross-reactivity exists between anti-ZIKV and anti-DENV 417 antibodies for the ZIKV and DENV polyproteins, and we show this technology can be used to 418 differentiate anti-ZIKV reactivity from cross-reactivity to many other arboviruses. Additionally, we 419 show the anti-NS2B1427-1451RD25 IgG response is susceptible to false positives in the context of 420 DENV infection and may be susceptible to false-positives in flavivirus-immune individuals. Thus, while this epitope may be broadly useful for serosurveillance, it should be used with caution in in any other pathogen. These findings merit further and more thorough investigation than this 473 current study can provide.
475
The peptide array technology used in this study has several limitations. The assay's utility could 476 be increased by the addition of quantitative capacities. We currently use a 1:100 antibody 477 dilution since we have found this to produce an optimal signal:noise ratio, but it is possible serial 478 dilutions could allow for measurement of quantitative results. Greater confidence in this assay's 479 results could be derived from assessing its ability to identify the binding of well-characterized 
489
The peptide array approach is also limited due to its reliance on continuous linear epitopes.
490
Many documented ZIKV epitopes are conformational discontinuous epitopes [49] [50] [51] [52] [53] [54] [55] . Other 491 epitope discovery methods will likely remain superior in defining discontinuous epitopes, but this 492 technology is useful in identifying immunoreactive regions not previously considered as potential 493 epitopes. Past work from our laboratory, including results from some of the animals whose sera 494 was analyzed here, has shown anti-ZIKV neutralizing antibody titers measured by PRNT90 do 495 not drop off but remain elevated as late as 64 dpi [16] . The discordance between levels of anti-antibodies do not play a role in protection against future infections, which may explain the drop-498 off in their production observed in macaques and in humans.
500
In the future, this technology could be expanded for use in profiling antibody responses to many 501 other pathogens. This tool was able to detect known and previously unknown epitopes 
